RxDoctor Payments Data

Britany Kelley

Family · San Antonio, TXNPI 1598116238

Payments from drug & device makers

$4,722in general payments, 2019–2025

Across 297 payments — averaging $15.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$970
  • Lilly USA, LLC$821
  • AstraZeneca$408
  • AbbVie$348
  • Merck$331
  • Astellas Pharma US Inc$270
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$4,61298%
  • Education$1102%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,722 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$16,869
Medicare patients
51
Services billed
324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide69$88,125
MounjaroTirzepatide22$42,843
TradjentaLinagliptin21$28,664
Repatha SureclickEvolocumab21$20,027
TrulicityDulaglutide13$19,752
FarxigaDapagliflozin Propanediol15$14,702
Praluent PenAlirocumab11$11,467
Tresiba Flextouch U-200Insulin Degludec11$9,464
SynthroidLevothyroxine Sodium32$3,294
Rosuvastatin Calcium150$1,339
Duloxetine Hcl38$1,329
Atorvastatin Calcium144$1,222
Gabapentin66$1,091
Fluticasone Propionate52$1,087
Metoprolol Succinate58$824

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$970$88,12569 claims
Lilly USA, LLCMounjaro, Trulicity$821$62,59535 claims
Boehringer IngelheimTradjenta$23$28,66421 claims
AstraZenecaFarxiga$408$14,70215 claims
AbbVieSynthroid$348$3,29432 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.

Other family in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →